SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

INVO Bioscience, Inc. INVO NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Devices • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

INVO Bioscience, Inc. (INVO) is a Medical - Devices company in the Healthcare sector, currently trading at $0.83. It has a SharesGrow Score of 27/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $6.5B, +72112.5%/yr average growth. Net income is $9.3B (loss), growing at -38755%/yr. Net profit margin is -143.1% (negative). Gross margin is 44% (-52.5 pp trend).

Balance sheet: total debt is $10.8B against $12.7B equity (Debt-to-Equity (D/E) ratio 0.85, moderate). Current ratio is 0.07 (tight liquidity). Debt-to-assets is 23.2%. Total assets: $46.4B.

Analyst outlook: 1 / 2 analysts rate INVO as buy (50%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 17/100 (Fail), Moat 40/100 (Fail), Future 40/100 (Partial), Income 10/100 (Fail).

INVO SharesGrow Score Overview

33/100

SharesGrow Score

Below average — proceed with caution

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 58/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 17/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 40/100

Gross margin is + market cap

FUTURE 40/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — INVO

No analyst coverage available for this stock.

INVO: +72112.5%/yr revenue is, -38755%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet INVO: Debt-to-Equity (D/E) ratio 0.85 (moderate), Current ratio is 0.07 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

INVO: Gross margin is 44% (-52.5 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 2 analysts rate INVO as buy (50%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

INVO: Net profit margin is -143.1%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.63-3.5

Volume124.02K

Avg Volume (30D)1.15M

Market Cap$3.25M

Beta (1Y)1.44

Share Statistics

EPS (TTM)-3,019.48

Shares Outstanding$3.1M

IPO Date2020-11-02

Employees25

CEOSteven M. Shum

Financial Highlights & Ratios

Revenue (TTM)$6.53B

Gross Profit$2.87B

EBITDA$-9.51B

Net Income$-9.35B

Operating Income$-8.13B

Total Cash$741.4M

Total Debt$10.78B

Net Debt$10.03B

Total Assets$46.45B

Price / Earnings (P/E)-0

Price / Sales (P/S)0

Analyst Forecast

Rating ConsensusBuy

Analysts Covering2

Buy 50% Hold 50% Sell 0%

Company Info

CountryUS

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINUS44984F4019

Price Chart

INVO

INVO Bioscience, Inc. ↗ · NASDAQ Capital Marke

Healthcare • Medical - Devices

0.63 52WK RANGE 3.50

People Also View

Entera Bio Ltd.

CLPS Incorporation

Lixte Biotechnology Holdings, Inc.

Enveric Biosciences, Inc.

NLS Pharmaceutics AG

Eli Lilly and Company

Johnson & Johnson

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message